secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-06-30T11:36:57+00:00
Accession:  0001104659-26-079087
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Therapeutics appoints Matthew Pauls to Board of Directors
------------------------------------------------------------------

- Board expanded from 7 to 8 members; Pauls appointed as Class I director effective June 29, 2026.
- Pauls is CEO of Savara (NASDAQ: SVRA) and has led rare disease biopharma companies including Strongbridge.
- He received an option to purchase 6,000 shares vesting monthly over 36 months under the Director Compensation Policy.
- Board determined Pauls is independent under Nasdaq listing rules; no related party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000110465926079087/0001104659-26-079087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000110465926079087/tm2619348d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-079087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer